Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Advanced Renal Cell Carcinoma
NCT04489771Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of belzutifan in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Sep 2020; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04489771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489771.